In last trading session, Adc Therapeutics SA (NYSE:ADCT) saw 1.08 million shares changing hands with its beta currently measuring 1.94. Company’s recent per share price level of $2.76 trading at -$0.09 or -3.16% at ring of the bell on the day assigns it a market valuation of $273.73M. That closing price of ADCT’s stock is at a discount of -49.64% from its 52-week high price of $4.13 and is indicating a premium of 61.96% from its 52-week low price of $1.05.
For Adc Therapeutics SA (ADCT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 7 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Adc Therapeutics SA (NYSE:ADCT) trade information
Upright in the red during last session for losing -3.16%, in the last five days ADCT remained trading in the red while hitting it’s week-highest on Wednesday, 06/18/25 when the stock touched $2.76 price level, adding 15.34% to its value on the day. Adc Therapeutics SA’s shares saw a change of 4.15% in year-to-date performance and have moved -15.34% in past 5-day. Adc Therapeutics SA (NYSE:ADCT) showed a performance of 13.58% in past 30-days.
Wall Street analysts have assigned a consensus price target of 8 to the stock, which implies a rise of 65.5% to its current value. Analysts have been projecting 7 as a low price target for the stock while placing it at a high target of 13. It follows that stock’s current price would drop -153.62% in reaching the projected high whereas dropping to the targeted low would mean a loss of -153.62% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 1.38% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 7.41% while estimates for its earnings growth in next 5 years are of 16.36%.
Adc Therapeutics SA (NYSE:ADCT)’s Major holders
REDMILE GROUP, LLC is the top institutional holder at ADCT for having 15.27 million shares of worth $48.25 million. And as of 2024-06-30, it was holding 15.9568 of the company’s outstanding shares.
The second largest institutional holder is PROSIGHT MANAGEMENT, LP, which was holding about 9.57 million shares on 2024-06-30. The number of shares represents firm’s hold over 10.0009 of outstanding shares, having a total worth of $30.24 million.
